[{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"9","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Genentech | Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech | Servier","highestDevelopmentStatusID":"6","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech | Servier"}]

Find Clinical Drug Pipeline Developments & Deals for Pegaspargase

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          July 18, 2025

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          November 02, 2022

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OHSU Knight Cancer Institute

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          OHSU Knight Cancer Institute

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          September 05, 2021

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Oregon Health and Science University | Genentech | Servier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 26, 2021

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Servier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          January 13, 2017

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Servier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Children's Oncology Group

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          January 02, 2017

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : EsPhALL | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Assistance Publique – Hôpitaux de Paris

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          March 23, 2016

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          June 17, 2013

                          Lead Product(s) : Peg L asparaginase

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Leadiant Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank